All In Biotech

Drug Trial Radar · NCT00190268

Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis

Multicentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Feb 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

126

Actual

Start

Feb 2005

Primary completion

Jun 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 19, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rational of study : 3,4-diaminopyridine is suspected to improved the fatigue associated in patient's multiple sclerosis. In order to confirm this hypothesis, a randomized, controlled versus placebo, double blinded study is performed.

Conditions

  • Multiple Sclerosis

Interventions

  • 3,4-diaminopyridineDrug

    3,4-diaminopyridine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. improvement of fatigue measured by a decrease of EMIF-SEP score compared to placebo group.Time frame: 43 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Henri Mondor Hospital

    Créteil, France

  • Pitié Salpetriere Hospital

    Paris, France

  • Tenon Hospital

    Paris, France

  • Pontchaillou Hospital

    Rennes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.